Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility

References

• WHO 20022009
   Google Scholar
• ManciaGDeBGDominiczakAGuidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J200728121462153617562668
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSKramerHHypertension treatment and control in five European countries, Canada, and the United StatesHypertension2004431101714638619
   PubMed Web of Science ®Google Scholar
• EisenSAMillerDKWoodwardRSSpitznagelEPrzybeckTRThe effect of prescribed daily dose frequency on patient medication complianceArch Intern Med19901509188118842102668
   PubMed Web of Science ®Google Scholar
• LeenenFHWilsonTWBolliPPatterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoringCan J Cardiol199713109149209374947
   PubMed Web of Science ®Google Scholar
• FinckeBGMillerDRSpiroAIIIThe interaction of patient perception of overmedication with drug compliance and side effectsJ Gen Intern Med19981331821859541375
   PubMed Web of Science ®Google Scholar
• MillerNHHillMKottkeTOckeneISThe multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionalsCirculation1997954108510909054774
   PubMed Web of Science ®Google Scholar
• BerlowitzDRAshASHickeyECInadequate management of blood pressure in a hypertensive populationN Engl J Med199833927195719639869666
   PubMed Web of Science ®Google Scholar
• OliveriaSALapuertaPMcCarthyBDL’ItalienGJBerlowitzDRAschSMPhysician-related barriers to the effective management of uncontrolled hypertensionArch Intern Med2002162441342011863473
   PubMedGoogle Scholar
• HymanDJPavlikVNSelf-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicineArch Intern Med2000160152281228610927724
   PubMedGoogle Scholar
• AldermanMWorld Health Organization– International Society of Hypertension Guideliines for the Management of HypertensionBealAKBlood Press19998Suppl 1943
   Google Scholar
• JuliusSWorldwide trends and shortcomings in the treatment of hypertensionAm J Hypertens2000135 Pt 257S61S10830790
   PubMedGoogle Scholar
• NICE costing reportURL: http://www.nice.org.uk/nicemedia/pdf/CG034costingreport.pdf 2002
   Google Scholar
• PittrowDKirchWBramlagePPatterns of antihypertensive drug utilization in primary careEur J Clin Pharmacol200460213514215042351
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakAGuidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 ReportJAMA2003289192560257112748199
   PubMed Web of Science ®Google Scholar
• StolkPVan WijkBLLeufkensHGHeerdinkERBetween-country variation in the utilization of antihypertensive agents: guidelines and clinical practiceJ Hum Hypertens2006201291792216988753
   PubMedGoogle Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• JamersonKABakrisGLWunCCRationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertensionAm J Hypertens200417979380115363822
   PubMed Web of Science ®Google Scholar
• BramlagePFixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertensionExp Opin Pharmacother2009101117551767
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ2003326740414271431
   Google Scholar
• FranklinSSNeutelJMDonovanMBouzamondoHIrbesartan/hydrochlorothiazide as initial therapy: subanalysis in patients with systolic BP > 180 mmHg and diastolic BP > 110 mmHg, efficacy and safetyJ Hypertens2008Suppl 1S159
   Google Scholar
• BönnerGFuchsWFixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertensionCurr Med Res Opin200420559760215140325
   PubMed Web of Science ®Google Scholar
• OparilSNewly emerging pharmacologic differences in angiotensin II receptor blockersAm J Hypertens2000131 Pt 218S24S10678284
   PubMed Web of Science ®Google Scholar
• FuchsBBreithaupt-GroglerKBelzGGComparative pharmacodynamics and pharmacokinetics of candesartan and losartan in manJ Pharm Pharmacol20005291075108311045887
   PubMed Web of Science ®Google Scholar
• LacourciereYAsmarRA comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigatorsAm J Hypertens19991212 Pt121181118710075377
   PubMedGoogle Scholar
• SeverPMichelJVoetBCandesartan cilexitil (CC): A meta-analysis of time-to-effect relationshipAm J Hypertens1998114 Pt 279A
   Google Scholar
• ElmfeldtDOlofssonBMeredithPThe relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacyBlood Press200211529330112458652
   PubMed Web of Science ®Google Scholar
• HimmelmannAKeinanen-KiukaanniemiSWesterARedonJAsmarRHednerTThe effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertensionBlood Press2001101435111332334
   PubMed Web of Science ®Google Scholar
• AnderssonOKNeldamSA comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertensionJ Hum Hypertens199711Suppl 2S63S649331011
   PubMed Web of Science ®Google Scholar
• ConwayJLauwersPHemodynamic and hypotensive effects of longterm therapy with chlorothiazideCirculation196021212713811661
   PubMed Web of Science ®Google Scholar
• PickkersPHughesADRusselFGThienTSmitsPThiazide-induced vasodilation in humans is mediated by potassium channel activationHypertension1998326107110769856976
   PubMedGoogle Scholar
• van BrummelenPMan int VeldAJSchalekampMAHemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonrespondersClin Pharmacol Ther19802733283366987024
   PubMed Web of Science ®Google Scholar
• CarterBLErnstMECohenJDHydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeabilityHypertension20044314914638621
   PubMed Web of Science ®Google Scholar
• AziziMNisse-DurgeatSFrench Collaborative GroupComparison of the antihypertensive effects of the candesartan 8 mg hydrochlorothiazide 12.5 mg combination vs the valsartan 80 mg hydrochlorothiazide 12.5 mg combination in patients with essential hypertension resistant to monotherapy. [abstract no. P2.367]J Hypertens200422Suppl 2S254S255
   Google Scholar
• OparilSMichelsonELLong term efficacy, safety, and tolerability of candesartan cilexitil added to hydrochlorothiazide in patients with severe hypertensionAm J Hypertens200912120
   Google Scholar
• EdesICombination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary careClin Drug Investig2009295293304
   PubMed Web of Science ®Google Scholar
• BramlagePSchonrockEOdojPWolfWPFunkenCImportance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZMMW Fortschritte der Medizin2008149Suppl 417218118402243
   PubMedGoogle Scholar
• UenSUnIFimmersRVetterHMengdenTEffect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertensionDeutsche medizinische Wochenschrift (1946)20071323818617219340
   PubMedGoogle Scholar
• BönnerGAntihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapyBlood Press200817Suppl 22230
   Web of Science ®Google Scholar
• OhmaKPMilonHValnesKEfficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension – comparison with a combination of losartan and hydrochlorothiazideBlood Press20009421422011055474
   PubMed Web of Science ®Google Scholar
• KönigWComparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: Results of the CARLOS-StudyClin Drug Invest2000194239246
   Google Scholar
• BramlagePHasfordJBlood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment–a reviewCardiovasc Diabetol200981819327149
   PubMed Web of Science ®Google Scholar
• SimonsLAOrtizMCalcinoGPersistence with antihypertensive medication: Australia-wide experience, 2004–2006Med J Aust2008188422422718279129
   PubMed Web of Science ®Google Scholar
• SjolieAKKleinRPortaMEffect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialLancet200837296471385139318823658
   PubMed Web of Science ®Google Scholar
• ChaturvediNPortaMKleinREffect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsLancet200837296471394140218823656
   PubMed Web of Science ®Google Scholar
• BelcherGLundeHElmfeldtDThe combination tablet of candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg has a tolerability profile similar to that of placebo [abstract]J Hypertens200018Suppl 2S94
   Google Scholar
• MengdenTVetterHToussetEUenSManagement of patients with uncontrolled arterial hypertension – the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZBMC Cardiovasc Disord200663616942618
   PubMedGoogle Scholar
• DicksteinKCohen-SolalAFilippatosGESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)Eur Heart J200829192388244218799522
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet2003362938677778113678871
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAThe ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke SurvivorsStroke20033471699170312817109
   PubMed Web of Science ®Google Scholar
• ElliottWJMeyerPMIncident diabetes in clinical trials of antihypertensive drugs: a network meta-analysisLancet2007369955720120717240286
   PubMed Web of Science ®Google Scholar
• LamSKOwenAIncident diabetes in clinical trials of antihypertensive drugsLancet200736995721513151417482972
   PubMedGoogle Scholar
• LindholmLHIbsenHDahlofBCardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet200235993111004101011937179
   PubMed Web of Science ®Google Scholar
• MacDonaldMRPetrieMCVaryaniFImpact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEur Heart J200829111377138518413309
   PubMed Web of Science ®Google Scholar
• YusufSOstergrenJBGersteinHCEffects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failureCirculation20051121485315983242
   PubMed Web of Science ®Google Scholar
• ZanchettiAElmfeldtDFindings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) – a reviewBlood Press2006152717916754269
   PubMed Web of Science ®Google Scholar
• LindholmLHPerssonMAlaupovicPCarlbergBSvenssonASamuelssonOMetabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)J Hypertens20032181563157412872052
   PubMed Web of Science ®Google Scholar
• KohKKQuonMJHanSHChungWJLeeYShinEKAntiinflammatory and metabolic effects of candesartan in hypertensive patientsInt J Cardiol200610819610016246439
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFCiccarelliLFogariRA randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitusClin Ther20032572006202112946547
   PubMedGoogle Scholar
• BilousRChaturvediNSjolieAKEffect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trialsAnn Intern Med20091511112019451554
   PubMed Web of Science ®Google Scholar
• TrenkwalderPLehtovirtaMDahlKLong-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetesJ Hum Hypertens199711Suppl 2S81S839331016
   PubMedGoogle Scholar
• MogensenCENeldamSTikkanenIRandomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) studyBMJ200032172741440144411110735
   PubMed Web of Science ®Google Scholar
• BurgessEMuirheadNRene deCPChiuAPichetteVTobeSSupramaximal dose of candesartan in proteinuric renal diseaseJ Am Soc Nephrol200920489390019211712
   PubMed Web of Science ®Google Scholar
• HallerHVibertiGCMimranAPreventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyJ Hypertens200624240340816508590
   PubMed Web of Science ®Google Scholar
• BakrisGLTotoRDMcCulloughPARochaRPurkayasthaDDavisPEffects of different ACE inhibitor combinations on albuminuria: results of the GUARD studyKidney Int200873111303130918354383
   PubMed Web of Science ®Google Scholar
• ChaturvediNPortaMKleinREffect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsLancet200837296471394140218823656
   PubMed Web of Science ®Google Scholar
• HubnerRHogemannAMSunzelMRiddellJGPharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteersJ Hum Hypertens199711Suppl 2S19S259331000
   PubMed Web of Science ®Google Scholar
• HanssonLLithellHSkoogIStudy on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristicsBlood Press200092314615110854001
   PubMedGoogle Scholar
• ZanchettiAElmfeldtDFindings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) – a reviewBlood Press2006152717916754269
   PubMed Web of Science ®Google Scholar
• Cohen-SolalAMcMurrayJJSwedbergKBenefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity programmeEur Heart J200829243022302818987098
   PubMedGoogle Scholar
• PloskerGLKeamSJCandesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertensionPharmacoeconomics200624121249127217129078
   PubMedGoogle Scholar